hit counter

Statins and Dementia Risk: No Long-Term Signal in 322,358 Patients

Statins do not look like a dementia-prevention drug, but they do not look like a dementia hazard either. In 322,358 Kaiser Permanente Northern California patients followed for an average of 11.8 years, dementia diagnoses rose right after statins were started, then flattened: after the first year, the hazard ratio for Alzheimer’s disease and related dementias …

Read more

Plasma p-tau217 Blood Test Predicts Alzheimer’s Risk 1.5x Stronger in APOE-e4

Photoreal illustration representing a blood biomarker test for Alzheimer's disease with imagery of blood vials, neurons, and APOE genetic motifs.

Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …

Read more